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ABSTRACT: Prostate specific antigen (PSA) does not provide the high reliability and precision that is 
required for an accurate screening for prostate cancer (PCa).  The aim of our study was to search for a simple, 
rapid, direct, preferably non-invasive, and highly accurate biomarker and procedure for the screening for PCa. 
For this purpose the level of Zn was prospectively evaluated in expressed prostatic fluid (EPF), obtained from 
38 apparently healthy males and from 33, 51, and 24 patients with chronic prostatitis, benign prostatic 
hyperplasia and PCa, respectively. Measurements were performed using an application of energy dispersive 
X-ray fluorescent (EDXRF) microanalysis developed by us. It was found that in the EPF of cancerous 
prostates the level of Zn was significantly lower in comparison with those in the EPF of normal, inflamed, and 
hyperplastic prostates. It was shown that “Sensitivity”, “Specificity” and “Accuracy” of PCa identification 
using the Zn level in the EPF samples were all significantly higher than those resulting from of PSA tests in 
blood serum. It was concluded that the Zn level in EPF, obtained by EDXRF, is a fast, reliable, and non-
invasive diagnostic tool that can be successfully used by local, non-urologist physicians at the point-of-care to 
provide a highly effective PCa screening and as an additional confirmatory test before a prostate gland biopsy. 
Keywords: Urology screening; Prostate cancer; Benign prostatic hyperplasia; Chronic prostatitis; Expressed 
prostatic fluid; Zn content; Energy-dispersive X-ray fluorescent analysis. 
1. INTRODUCTION 
Prostate cancer (PCa) is one of the most important medical, scientific and public health problems. 
Worldwide, PCa is the fifth leading cause of cancer deaths and the second most commonly diagnosed cancer 
in men [1]. PCa is especially prevalent in North America, Northern and Western Europe and Australia [2]. For 
example, the American Cancer Society declares PCa, with a lifetime prevalence of one in six men, is the most 
common cancer in males and the second leading cause of cancer death [3]. In terms of incidence and mortality 
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PCa is also the leading cancer in men from Africa, Oceania, and the Caribbean [1, 2]. PCa has also become a 
major public health concern in China [4]. 
The survival rate is proportional to the stage reached at diagnosis, hence early-stage diagnosis using 
effective diagnostic tools is a key to reducing mortality due to PCa [5]. It is widely acknowledged that 
screening and early diagnosis of PCa are of vital importance for improving the likelihood of recovery. Current 
screening relies on prostate-specific antigen (PSA) testing in blood serum and a PSA level of 4 ng/ml is used 
as the highest level compatible with non-malignant conditions. However, PSA screening of PCa has some 
significant disadvantages.   
Firstly, PSA is not a cancer-specific biomarker. So there can be an elevated serum concentration 
(above 4 ng/ml) among patients with benign prostate hyperplasia (BPH) and urogenital infections, including 
chronic prostatitis (CP). Reliance on PSA testing can result in significant over-detection of alleged PCa and 
hence inappropriate treatment of non-malignant disease [6]. Nearly 70-75% of prostate biopsies fail to detect 
PCa in men who undergo prostate biopsy procedures due to elevated PSA levels discovered after blood 
serum-test screening [5, 7]. In other words, it has been confirmed that only 25-30% of patients with a PSA 
value ≥4 ng/ml were finally diagnosed with PCa, leading to the over-treatment of low-risk patients, 
unnecessary biopsies and nonessential radical prostatectomies [8]. Thus, the level of PSA test specificity 
(selectivity) can be estimated as about 25-30%. 
Secondly, the PSA test misses some aggressive tumors. For example, as was found by Thompson et al. 
[9] that 20-25% men diagnosed with PCa including those with a poorly differentiated form (Gleason Score 
≥8) have PSA levels below 4 ng/ml [6, 9]. Data from other research shows that only 40% of patients with PCa 
have an abnormal PSA level [10]. Thus, the PSA test’s sensitivity can be estimated as somewhere between 
40-75%. 
The limitations and potential harm associated with PSA screening stimulate investigation of novel 
biomarkers with superior ability to detect PCa, compared with traditional PSA tests, so decreasing 
unnecessary biopsies. Much attention is now turning to fluid-based biomarkers, because obtaining fluid 
samples is in effect a minimally invasive liquid biopsy. Other relevant factors of great significance for any 
novel method of PCa detection include cost-effectiveness, capacity to generate real-time results, “simplicity-
of-use”, robustness, and functionality without excessive prior-processing of samples [11]. 
In our previous studies the significant role of Zn, Ca, Mg, Rb and some other trace elements (TEs) in 
the function of the prostate was studied [12-22]. One of the main functions of the gland is the production of 
prostatic fluid [23]. It contains a high levelof Zn, Ca, Mg, Rb, and some other TEs, in comparison with 
concentrations of these elements in serum and other human body fluids. 
The first finding of remarkably high levels of Zn in human expressed prostatic fluid (EPF) was 
reported in the early 1960s [24]. After analyzing EPF expressed from the prostates of 8 apparently healthy 
men, aged 25-55 years, it was found that Zn concentrations varied from 300 to 730 mg/l. After this finding 
several investigators suggested that the measurement of Zn levels in EPF may be useful as a marker of 
abnormal prostate secretory function [25, 26]. This suggestion promoted more detailed studies of the Zn 
concentrations in the EPF of healthysubjects and in those with different prostatic diseases, including PCa [26, 
27]. A detailed review of these studies was given in our earlier publication [27]. Moreover, the method and 
apparatus for micro analysis of Zn and some other TEs in the EPF samples using energy dispersiveX-ray 
fluorescence (EDXRF) activated by radiation from the radionuclide source 109Cd (109Cd EDXRF) was 
developed by us [28]. We reasoned that apart from total amounts of TEs the ratios of Zn to some other TE 
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content in EPF are likely to reflect a disturbance of prostate function. It was found that data on changes of TE 
content and Zn/TE concentration ratios in EPF of patients with PCa are very important, because these 
significant changes increase our knowledge and recognition of PCa pathogenesis and may prove useful as 
PCa diagnostic markers [29-39]. 
The main objective of present study was to obtain reliable results about the Zn concentrations in the 
EPF of healthy men as well as in the EPF of patients with CP, BPH and PCa using the 109Cd EDXRF method. 
The second aim was to compare the Zn levels of EPF investigated for normal, inflamed, hyperplastic, and 
cancerous prostates. The final aim was to evaluate appropriate characteristics of Zn level in EPF as potential 
diagnostic test, with regard to its sensitivity, specificity, and accuracy.   
All studies were approved by the Ethical Committees of the Medical Radiological Research Centre 
(MRRC), Obninsk. All the procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments, or with comparable ethical standards.  
2. MATERIALS AND METHODS 
2.1. Samples 
Specimens of EPF were obtained from 38 men with apparently normal prostates (N, mean age ± 
Standard Deviation - 59±11 years), from 33 males with CP (mean age 50±9 years), from 51 patients with 
BPH (mean age 63±6 years), and from 24 patients with PCa (mean age 65±10 years) in the Urological 
Department of MRRC using a standard rectal massage procedure. The diagnosis of each prostate condition 
was made by qualified urologists. In all cases the N classification and CP diagnosis were confirmed by 
clinical examination and by cytological and bacteriological investigations of the EPF samples. The diagnosis 
of BPH or PCa had been confirmed by clinical examination and morphological results obtained during studies 
of biopsy and resected materials. Subjects were asked to abstain from sexual intercourse for three days 
preceding the procedure. Specimens of EPF were obtained in sterile containers, which were appropriately 
labeled. Twenty μl (microliters) of fluid were taken in duplicate by micropipette from every specimen for TE 
analysis, while the rest of the fluid was used for cytological and bacteriological investigations. One 20 μl 
sample of the EPF was dropped on a 11.3 mm diameter disk made of thin, ash-free filter paper fixed on pieces 
of adhesive tape and dried in a desiccator at room temperature. Then the dried sample was covered with a 4 
μm gage Dacron film and centrally pulled onto a Plexiglas cylindrical frame [28]. 
2.2. Standards and certified reference material 
To determine concentration of the Zn by comparison with known standards, aliquots of solutions of 
commercial, chemically pure compounds were used for calibration [40]. The standard samples for calibration 
were prepared in the same way as the samples of prostate fluid. Because there were no available liquid 
Certified Reference Materials (CRMs), ten sub-samples of the powdered CRM IAEA H-4 (animal muscle) 
were analyzed to estimate the precision and accuracy of results. Every CRM sub-sample weighing about 3 mg 
was applied to the piece of adhesive tape serving as an adhesive fixing backing. An acrylic stencil made in the 
form of a thin-walled cylinder with 11.3 mm inner diameter was used to apply the sub-sample to the adhesive 
tape. The polished-end acrylic pestle, which is a constituent of the stencil set, was used for uniform 
distribution of the sub-sample upon the adhesive tape surface restricted by the stencil’s inner cylindrical 
surface. After the sub-sample was lightly pressed onto the adhesive tape carrier, the stencil was removed. 
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Then the sub-sample was covered with 4 μm gage Dacron film. Before the sample was applied, pieces of 
adhesive tape and Dacron film were weighed using an analytical balance. They were reweighed after the 
sample had been placed inside to determine precisely the sub-sample mass. 
2.3. Instrumentation and method 
The facility for the radionuclide-induced EDXRF included an annular 109Cd source with an activity of 
2.56 GBq, A Si(Li) detector with an electric cooling system and a portable multi-channel analyzer based on 
apersonal computer, comprised the detection system. Its resolution was 270 eV at the 6.4 keV line. The 
facility functioned as follows. Photons with energy 22.1 keV from the 109Cd source arrived at the surface of 
the specimen inducing fluorescent Kα X-rays from the Zn. The fluorescence reached the detector after passing 
through a 10 mm diameter collimator. Then the X-ray’s arrival was recorded. The duration of the 
measurements of Zn concentration was 60 min for each sample. The intensityof theKα-line of Zn for EPF 
samples and standards was estimated from a calculation of the total area under the corresponding photo peak 
in the spectra. 
2.4. Computer programs and statistic 
All EPF samples for EDXRF were prepared in duplicateand mean value of Zn content was used in the 
final calculation. Using the Microsoft Office Excel programs, some statistical characteristics, such as 
arithmetic mean (M), standard deviation (SD), standard error of the mean (SEM), minimum and maximum 
values (Range), and median were calculated for Zn concentrationsin the EPF of normal (N), CP, BPH, and 
PCa prostates. The difference in the results between the five pairs of samples (N and CP, N and BPH, N and 
PCa, PCa and CP, PCa and BPH) was evaluated by the parametric Student's t-test and non-parametric 
Wilcoxon-Mann-Whitney U-test. Values of p<0.05 were considered to be statistically significant. For the 
construction of diagram illustrating individual data set for Zn concentrations in the EPF of normal, inflamed, 
benign hyperplastic and cancerous prostates, the Microsoft Office Excel software was also used. 
3. RESULTS 
Tables 1 and 2 depict some statistical characteristics of the Zn concentrations investigated and relevant 
to a normal distribution (M, SD, and SEM) (Table 1) and appropriate for a distribution that may not 
necessarily be normal (Median, Range) (Table 2).  
The ratios of means/medians and the difference between mean/median values of Zn concentration in 
EPF samples of normal, inflamed, benign hyperplastic and cancerous prostates determined by the parametric 
Student's t-test and non-parametric Wilcoxon-Mann-Whitney U-test are presented in Tables 3 and 4, 
respectively.  
 
Table 1. Mean values of the Zn concentration (mg/l) in prostate fluid of normal (N), inflamed (CP), benign hyperplastic 
(BPH) and cancerous prostate (PCa). 
Element 
Prostate fluid 
N 
41-82 years (n=38) 
CP 
37-65 years (n=33) 
BPH 
52-75 years (n=51) 
PCa 
47-77 years (n=24) 
Mean±SD(SEM) Mean±SD(SEM) Mean±SD(SEM) Mean±SD(SEM) 
Zn 598±207(34) 382±275(48) 488±302(42) 62.0±98.3(20.1) 
Mean – arithmetic mean, SD – standard deviation, SEM – standard error of mean. 
 
Zaichick & Zaichick   Zinc of prostatic fluid in prostate cancer diagnostics 5 
MicroMedicine 2020; 8(1): 1-11 
 
Table 2. Median and range of Zn concentration (mg/l) in prostate fluid of normal (N), inflamed (CP), benign hyperplastic 
(BPH) and cancerous prostate (PCa). 
Element 
 
Prostate fluid 
N 
41-82 years (n=38) 
CP 
37-65 years (n=33) 
BPH 
52-75 years (n=51) 
PCa 
47-77 years (n=24) 
Median(Range) Median(Range) Median(Range) Median(Range) 
Zn 560(253-948) 295(62.0-1051) 427(45.0-977) 21.6(2.82-371) 
 
Table 3. Ratio of means and the difference (Student’s t-test) between mean values of Zn concentration (mg/l) in prostate 
fluid of normal (N), inflamed (CP), benign hyperplastic (BPH) and cancerous prostate (PCa). 
CP and N BPH  and N PCa and N PCa and CP PCa and BPH 
Ratio 
CP/N p≤ 
Ratio 
BPH/N p≤ 
Ratio 
PCa/N p≤ 
Ratio 
PCa/CP p≤ 
Ratio 
PCa/BPH p≤ 
0.64 0.001 0.82 0.044 0.104 0.001 0.16 0.001 0.13 0.001 
 
Table 4. Ratio of medians and the difference (Wilcoxon-Mann-Whitney U-test) between mean values of Zn concentration 
(mg/l) in prostate fluid of normal (N), inflamed (CP), benign hyperplastic (BPH) and cancerous prostate (PCa). 
CP and N BPH  and N PCa and N PCa and CP PCa and BPH 
Ratio 
CP/N p 
Ratio 
BPH/N p 
Ratio 
PCa/N p 
Ratio 
PCa/CP p 
Ratio 
PCa/BPH p 
0.53 <0.01 0.76 <0.01 0.039 <0.01 0.073 <0.01 0.051 <0.01 
 
Table 5 contains important parameters (“Sensitivity”, “Specificity” and “Accuracy”), which reflect the 
possibilities that Zn concentration in prostate fluid can aid the diagnosis of PCa (estimation is made for “PCa 
or normal, CP, and BPH”). A calculation was done under such conditions as: if the level of “Sensitivity” was 
chosen as 100%, if the level of “Specificity” was chosen as 100%, and if the level of “Sensitivity” was not 
below 80% (optimal). 
 
Table 5. Parameters of the importance (“Sensitivity”, “Specificity” and “Accuracy”) of Zn concentration in prostate fluid 
for the diagnosis of PCa (estimation is made for “PCa or normal, CP, and BPH”). 
Chosen parameter(s) Upper limit for PCa 
Sensitivity 
% 
Specificity 
% 
Accuracy 
% 
“Sensitivity” was chosen as 100% 371 mg/l 100 60±5 66±5 
“Specificity” was chosen as 100% 45 mg/l 63±10 100 94±2 
Optimal levels of “Sensitivity”, “Specificity” 
and “Accuracy” (“Sensitivity” ≥ 80%) 120 mg/l 92±6 92±3 92±2 
 
Individual data set for the Zn concentration investigated in EPF samples of normal, inflamed, benign 
hyperplastic and cancerous prostates are shown in Figure 1. 
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Figure 1. Individual data set for Zn concentrations (mg/l) in prostate fluid of normal (1), inflamed (2), benign hyperplastic 
(3) and cancerous prostate (4). 
 
4. DISCUSSION 
As was shown by us [27-39] results from the use of CRM IAEA H-4 as certified reference materials 
for the analysis of samples of EPF is acceptable. Good agreement of the Zn content, analyzed by the 109Cd 
EDXRF method, with the certified data of reference materials indicates an acceptable accuracy for the results 
obtained in the study and presented in Tables 1-5. 
From Tables 3 and 4, it is observed that in the EPF of inflamed and hyperplastic prostates the 
mean/median values of Zn are significantly lower than normal levels. 
In the EPF of cancerous prostates the mean/median values of Zn are drastically lower than normal 
levels. Moreover, these differences also exist when EPFs of cancerous prostates are compared with EPFs of 
inflamed or hyperplastic prostates (Tables 3 and 4). 
Thus, from Tables 3 and 4, as well as from individual data set (Figure 1), it is observed that 
measurements of the Zn concentration in EPF could become a powerful diagnostic tool when seeking PCa. To 
a large extent, continuation of the search for new methods for early diagnosis of PCa was due to experience 
gained after a critical assessment of the limitations of the current PSA blood serum tests [5-11, 41]. In 
addition to the PSA test and morphological study of needle-biopsy cores of the prostate, the development of 
highly precise less invasive testing methods will clearly be very useful. The proportion of subjects with of 
normal, inflamed, benign hyperplastic and cancerous prostates in the present study reproduced the Urological 
Department’s usual patient proportions in the MRRC. Thus, our data allow us to evaluate adequately the 
importance of Zn concentration in EPF for the diagnosis of PCa.  
The equations for calculation of such important characteristics of the diagnostic test as “Sensitivity”, 
“Specificity/Selectivity” and “Accuracy” are well known [42]. They comprise: 
Sensitivity = {True Positives (TP)/[TP + False Negatives (FN)]}×100%  
Specificity = {True Negatives (TN)/[TN + False Positives (FP)]}×100%  
Accuracy = [(TP+TN)/(TP+FP+TN+FN)]×100% 
For example, if “Sensitivity” of a new method of PCa diagnosis is set equal to 100% the resulting 
values for “Specificity/Selectivity” and “Accuracy” are presented in Table 5. If “Specificity/Selectivity” of a 
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new method of PCa diagnosis is set equal to 100% the resulting values for “Sensitivity” and “Accuracy” are 
also presented in Table 5. The data for “Sensitivity”, “Specificity/Selectivity” and “Accuracy” can be more 
balanced if a level of ≥ 80% for “Sensitivity” is acceptable. It should be noted that the number of people 
(samples) examined was taken into account for calculation of confidence intervals of data presented in Table 
5 [42].   
From data in Table 5 it follows, after comparison, that levels of “Sensitivity”, “Specificity/Selectivity” 
and “Accuracy” for the Zn in EPF used as PCa biomarker are better than results from the PSA level blood 
serum test. In other words, if level of Zn concentration in EPF sample is lower than 120 mg/l, one could 
diagnose a malignant tumor with an accuracy 92±2%. Thus, using the level of Zn in an EPF sample as a 
tumor marker makes it possible to diagnose cancer in the 92±6% of cases (sensitivity) with 
specificity/selectivity 92±3%. The high level of specificity/selectivity, 92±3%, means that this test results in a 
significant decrease in the number of unnecessary biopsies, because on average only 8% (100%-92% = 8%) 
of prostate biopsies fail to detect PCa (i.e. are false negative) in men who have prostate cancer. Thus, using 
the proposed test will reduce the number of true negatives after biopsy.  
Characteristically, elevated or deficient levels of TEs and electrolytes observed in the EPF of 
cancerous prostates are discussed in terms of their potential role in the initiation, promotion, or inhibition of 
prostate cancer. In our opinion, abnormal levels of TE contents in the EPF of cancerous prostates could be the 
consequences of malignant transformation. Compared to other fluids of the human body, the prostate’s 
secretion contains higher levels of Zn. These data suggest that this element could be involved in prostatic 
function. The suppressed prostatic function can be both a cause and a consequence of CP or BPH. Malignant 
transformation is accompanied by a drastic loss of tissue-specific functional features, which leads to a 
significant reduction in the Zn content associated with functional characteristics of the human EPF.  
It is necessary to keep in mind that biochemical, or in other words functional, changes in prostatic cells 
are present from the earliest development of malignancy, which precedes any histopathological indication of 
malignancy, and these biochemical changes persist during progression of the malignancy and remain present 
in advanced prostate cancer. Thus, Zn depletion is an early step in the cancer proliferation process and Zn 
depletion in EPF precedes the morphological transformation of cells from being histopathologically normal to 
cancerous. 
In our study the portable device we used for EDXRF analysis, with its 109Cd source for the excitation 
of X-ray fluorescence in the EPF sample, was developed by ourselves. More powerful devices for EDXRF 
analysis with X-ray tubes, including “the total reflection” version (TRXRF) of the method, allow reliable 
determinations of Zn and many other TE concentrations in a drop of a human body fluid within 10 min [43]. 
EDXRF is a fully instrumental and non-destructive method because a drop of EPF is investigated without 
requiring any sample pretreatment or its consumption. Moreover, it is well known that among the most 
modern analytical technologies, EDXRF is one of the simplest, fastest, most reliable and efficient of the 
available techniques for TE determination [43]. There are many different kinds of EDXRF and TRXRF 
device on the market and technical improvements are frequently announced. 
The routine screening for PCa has generally included invasive (by a venipuncture) testing of PSA 
level in blood serum. The method presented here for PCa screening is a noninvasive and safe procedure 
because only requires a drop of EPF. This is obtained during a digital rectal examination using prostate gland 
massage. Many urologists have successfully and easily obtained EPF this way, so it seems likely that others 
will be able to do likewise for most of their patients. 
Zaichick & Zaichick   Zinc of prostatic fluid in prostate cancer diagnostics 8 
MicroMedicine 2020; 8(1): 1-11 
All of these advantages, including the elimination of CP and BPH as confounding conditions when 
screening for PCa, along with its “Sensitivity”, “Specificity” and “Accuracy” for PCa identification all 
exceeding 90%, favor the EDXRF of TEs in EPF over the use of PSA levels for this purpose. Also these 
results suggest a strong possibility that it can replace the PSA level determination in screening for PCa. In our 
opinion, obtaining the Zn level in a drop of EPF, using EDXRF, is a fast, reliable, and non-invasive diagnostic 
tool that can be successfully used by physicians, who are not urologists, at the point-of-care for highly 
effective PCa screening and as an additional test before prostate gland biopsy. Its advantages have been 
outlined above. Further we believe it is superior to the PSA level determination for this purpose.   
5. CONCLUSION  
There is a critical need for a highly reliable, accurate, simplified biomarker and procedure for the 
screening for prostate cancer, or as an adjunct for the PSA test during the urological examination of patients 
as candidates for prostate biopsy. In the present work, Zn concentration measurements were carried out in the 
EPF samples from normal, inflamed, hyperplastic, and malignant prostates using the non-destructive, 
instrumental 109Cd EDXRF micro method developed by us. It was shown that this method is an adequate 
analytical tool for the non-destructive determination of Zn concentrations in the EPF samples of human 
prostate in normal and some pathological conditions. It was observed that in the EPF of cancerous prostates, 
levels of Zn were significantly lower in a comparison with those in the EPF of normal, inflamed, and 
hyperplastic prostates. It was shown that “Sensitivity”, “Specificity” and “Accuracy” of PCa identification 
using the Zn level in the EPF samples was significantly higher than that using PSA levels in blood serum. It 
was concluded that study of the Zn level in an EPF drop, obtained by using EDXRF, is a fast, reliable, and 
non-invasive diagnostic tool that can be successfully used by physicians at the point-of-care for highly 
effective PCa screening and as an additional test before a prostate gland biopsy. 
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